[go: up one dir, main page]

WO2014155278A3 - Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 - Google Patents

Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 Download PDF

Info

Publication number
WO2014155278A3
WO2014155278A3 PCT/IB2014/060110 IB2014060110W WO2014155278A3 WO 2014155278 A3 WO2014155278 A3 WO 2014155278A3 IB 2014060110 W IB2014060110 W IB 2014060110W WO 2014155278 A3 WO2014155278 A3 WO 2014155278A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
patient
antagonist
treating
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/060110
Other languages
English (en)
Other versions
WO2014155278A2 (fr
Inventor
Arndt Holger BRACHAT
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2014155278A2 publication Critical patent/WO2014155278A2/fr
Publication of WO2014155278A3 publication Critical patent/WO2014155278A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouvelles méthodes prédictives et thérapies personnalisées destinées au traitement d'une maladie auto-immune (AI) choisie parmi le psoriasis, l'uvéite, la polyarthrite rhumatoïde (PR), le rhumatisme psoriasique (RP), la spondylarthrite ankylosante (SA) et la sclérose en plaques (SEP) Plus particulièrement, l'invention concerne des méthodes de traitement d'un patient atteint d'une maladie AI par administration sélective d'un antagoniste de l'IL-17, par exemple, d'un anticorps anti-IL-17, tel que le sécukinumab, audit patient sur la base du fait que ce patient présente une prédisposition génétique à développer une réponse favorable au traitement par l'antagoniste de l'IL-17. L'invention concerne en outre des sources d'information sous forme transmissible, des méthodes diagnostiques et des trousses servant à prédire la probabilité qu'un patient atteint d'uvéite, de PR, RP, SA, psoriasis ou SEP développe une réponse au traitement par un antagoniste de l'IL-17, par exemple, un anticorps anti-IL-17, tel que le sécukinumab.
PCT/IB2014/060110 2013-03-26 2014-03-24 Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 Ceased WO2014155278A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361805257P 2013-03-26 2013-03-26
US61/805,257 2013-03-26

Publications (2)

Publication Number Publication Date
WO2014155278A2 WO2014155278A2 (fr) 2014-10-02
WO2014155278A3 true WO2014155278A3 (fr) 2014-12-18

Family

ID=50513390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060110 Ceased WO2014155278A2 (fr) 2013-03-26 2014-03-24 Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17

Country Status (1)

Country Link
WO (1) WO2014155278A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251174T1 (hr) 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6931648B2 (ja) 2015-10-27 2021-09-08 ユーシービー バイオファルマ エスアールエル 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
WO2017221174A1 (fr) * 2016-06-22 2017-12-28 Novartis Ag Méthodes de traitement du vitiligo à l'aide d'anticorps de l'interleukine-17 (il -17)
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
EP4031570A1 (fr) * 2019-09-20 2022-07-27 Novartis AG Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'interleukine-17 (il-17)
US12157891B2 (en) * 2021-10-14 2024-12-03 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (fr) * 2003-11-21 2005-06-09 Celltech R & D Limited Methode de traitement de la sclerose en plaques par inhibition de l'activite d'il-17
US7807155B2 (en) * 2004-08-05 2010-10-05 Novartis Ag IL-17 antagonistic antibodies
WO2013158821A2 (fr) * 2012-04-20 2013-10-24 Novartis Ag Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
AU2003223214B2 (en) 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (fr) 2006-11-10 2012-08-08 UCB Pharma, S.A. Anticorps et diagnostic
MX2009008096A (es) 2007-02-02 2009-08-07 Novartis Ag Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
BRPI0819688A2 (pt) 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
WO2010034443A1 (fr) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Anticorps contre l'il 17 humaine et utilisations associees
HRP20251174T1 (hr) 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
WO2012082573A1 (fr) 2010-12-13 2012-06-21 Novartis Ag Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (fr) * 2003-11-21 2005-06-09 Celltech R & D Limited Methode de traitement de la sclerose en plaques par inhibition de l'activite d'il-17
US7807155B2 (en) * 2004-08-05 2010-10-05 Novartis Ag IL-17 antagonistic antibodies
WO2013158821A2 (fr) * 2012-04-20 2013-10-24 Novartis Ag Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAETEN DOMINIQUE ET AL: "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial", November 2013, LANCET (NORTH AMERICAN EDITION), VOL. 382, NR. 9906, PAGE(S) 1705-1713, ISSN: 0140-6736(print), XP002726555 *
LEONARDI CRAIG ET AL: "Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis", March 2012, NEW ENGLAND JOURNAL OF MEDICINE, VOL. 366, NR. 13, PAGE(S) 1190-1199, ISSN: 0028-4793(print), XP002726553 *
PAPP KIM A ET AL: "Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis", March 2012, NEW ENGLAND JOURNAL OF MEDICINE, VOL. 366, NR. 13, PAGE(S) 1181-1189, ISSN: 0028-4793(print), XP002726554 *

Also Published As

Publication number Publication date
WO2014155278A2 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
WO2014155278A3 (fr) Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
MX2016013372A (es) Metodos de tratar selectivamente el asma utilizando antagonistas de il-13.
WO2013158821A3 (fr) Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
MX392435B (es) Anticuerpos estables y solubles que inhiben el vegf.
MX2021005193A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
JOP20140049B1 (ar) أجسام مضادة ترتبط بـ il-23
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
MY156353A (en) Methods of treating autoimmune diseases with dll4 antagonists
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
UA116614C2 (uk) Антитіло до фактора d і його застосування
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
PH12012501617A1 (en) Antagonist anti-il-7 receptor antibodies and methods
NZ719654A (en) Interleukin-2 fusion proteins and uses thereof
WO2012118750A3 (fr) Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
NZ630865A (en) Anti-baff-anti-il-17 bispecific antibodies
WO2012059598A3 (fr) Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
PH12022551580A1 (en) Anti-ctla-4 antibody and use thereof
HK1250176A1 (zh) 用於确定细胞疗法的临床反应的生物标志物
Berra et al. Use of a Monoclonal antibody (5H5) recognizing FH but not FHL-1 and FHRs to study FH in aHUS patients
UA110226C2 (en) Antibodies to cd38
TH1701000202A (th) การทำให้เกิดการกลายพันธุ์เฉพาะตำแหน่งของแอนติบอดี trem-1 เพื่อลดความหนืด

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718170

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718170

Country of ref document: EP

Kind code of ref document: A2